InsiderSignal.AI

InsiderSignal.ai

MLYS - Mineralys Therapeutics, Inc.

Insider Purchase by Ra Capital Management, L.P. (Dir)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

5 months ago, Ra Capital Management, L.P., serving as Dir at Mineralys Therapeutics, Inc. (MLYS), purchased 1,176,470 shares at $25.50 per share, for a total transaction value of $29,999,985.00. Following this transaction, Ra Capital Management, L.P. now holds 7,323,750 shares of MLYS.

This purchase represents a 19.00% increase in Ra Capital Management, L.P.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, September 4, 2025 and publicly disclosed via SEC Form 4 filing on Monday, September 8, 2025, 4 days after the trade was made.

Mineralys Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Ra Capital Management, L.P.

Ra Capital Management, L.P.

Dir

RA Capital Management, L.P. is a Boston-based investment firm specializing in public and private investments in healthcare, biotechnology, life sciences, and planetary health.[[1]](https://en.wikipedia.org/wiki/RA_Capital_Management)[[2]](https://www.racap.com/about-us) Founded in 2001 by Richard Aldrich, a co-founder of Vertex Pharmaceuticals, the firm officially launched in 2004 as a hedge fund focused on public companies before expanding into private investments, company formation, and venture funding.[[1]](https://en.wikipedia.org/wiki/RA_Capital_Management)[[2]](https://www.racap.com/about-us) The firm manages approximately $5.94 billion in assets as of mid-2025, with a portfolio spanning global therapeutic areas and development stages, including top holdings like Ascendis Pharma (29.9%) and Vaxcyte (6.55%).[[3]](https://whalewisdom.com/filer/ra-capital-management-llc) RA Capital has launched multiple venture funds, such as Nexus Fund III ($880 million in 2021), and operates incubators like Carnot and RAVentures to nurture early-stage biotech companies.[[1]](https://en.wikipedia.org/wiki/RA_Capital_Management)[[2]](https://www.racap.com/about-us) As a corporate insider designated as 'Dir, 10%' at Climb Bio, Inc. (CLYM), it holds significant stakes through affiliates like Sera Medicines, LLC, reflecting its active role in biotech investments.[[3]](https://whalewisdom.com/filer/ra-capital-management-llc)

View full insider profile →

Trade Price

$25.50

Quantity

1,176,470

Total Value

$29,999,985.00

Shares Owned

7,323,750

Trade Date

Thursday, September 4, 2025

171 days ago

SEC Filing Date

Monday, September 8, 2025

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Mineralys Therapeutics, Inc.

Company Overview

No company information available
View news mentioning MLYS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/249320

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime